Alcon爱尔康品牌怎么样 申请店铺

我要投票 Alcon爱尔康在医疗器械行业中的票数:186 更新时间:2025-01-23
Alcon爱尔康是哪个国家的品牌?「Alcon爱尔康」是爱尔康(中国)眼科产品有限公司旗下著名品牌。该品牌发源于美国,在1945年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
Alcon爱尔康怎么样

始于1945年美国,2008年被诺华公司收购,全球眼科领域的领先者,专业研究、发展、服务及制造光学及眼科产品的世界级厂商


爱尔康公司 (Alcon Laboratories, Inc.) 成立于1945年,是全球较大的眼科药品与医疗器械专业公司。在全球75个国家和地区设有分公司,拥有15,000多名员工,5个研发中心,14个生产工厂,产品销售遍及180多个国家和地区。

2008诺华公司收购眼部护理公司Alcon股份。合并完成后,爱尔康成为诺华旗下第二大的部门。视康(CIBA VISION)和选出的数种诺华眼科医药将被整合进爱尔康,从而形成销售额超过87亿美元、覆盖超过70%的眼科护理领域的组织。

爱尔康的使命是通过创新型产品,提高视觉质量,提高生活品质。这个使命意味着爱尔康22000多名员工为“保护、恢复和提高视力”的目标进行着不懈的努力与奋斗,使散光治疗,青光眼治疗,近视眼激光视力恢复矫正等等技术得到更好,努力改善更多人的视力健康。

在全球范围内,爱尔康有近2000名员工专注于研发工作,以满足世界上迫切的眼部护理需求。

此外,爱尔康与眼科保健专业人士和人道主义组织建立了紧密的合作关系,共同专注于医疗使命并在世界上需要救助的社区进行防盲活动。世界上存在着很多未解决的眼科问题,全世界有数百万人不能得到常规性眼科护理,大量实质性工作亟待完成。基于数十年的专业经验,爱尔康将继续专注于促进眼科保健行业的发展。

爱尔康于1995年作为法人实体进入中国。今天,爱尔康中国在全国范围内拥有700余名员工服务于我们的眼科保健专家。我们的企业目标是在手术产品、药品及视力保健领域成为患者的选择。爱尔康中国一贯秉承其对中国眼科医生及患者的承诺,不断加强相互间的合作,携手共创辉煌的明天。

爱尔康中国同中华医学会眼科学分会紧密合作,举办各种规模及各种类型的学术研讨会,全国眼科年会,以及国际眼科会议;为国内眼科医生的学术交流活动创造平台,为推动中国眼科事业的发展做出不懈的努力。此外,爱尔康中国还同中国残联,健康快车等慈善机构紧密合作,支持各种扶贫项目,为中国的防盲治盲工作贡献力量。


Founded in 1945 in the United States and acquired by Novartis in 2008, Alcon laboratories, Inc., a global leader in ophthalmology and a world-class manufacturer specializing in research, development, service and manufacturing of optical and ophthalmic products, was established in 1945 as the world's largest professional company of ophthalmic drugs and medical devices. It has branches in 75 countries and regions, more than 15000 employees, 5 R & D centers, 14 production plants, and product sales in more than 180 countries and regions. In 2008, Novartis acquired the shares of Alcon, an eye care company. After the merger, Alcon became the second largest division of Novartis. Cibavision and several selected Novartis ophthalmic medicines will be integrated into Alcon to form an eye care organization with sales of over $8.7 billion and coverage of over 70%. Alcon's mission is to improve visual quality and quality of life through innovative products. This mission means that more than 22000 employees of Erkang are making unremitting efforts and struggles for the goal of "protecting, restoring and improving vision", so that astigmatism treatment, glaucoma treatment, myopia laser vision restoration and correction and other technologies can be better, and efforts can be made to improve the visual health of more people. Globally, Alcon has nearly 2000 employees focused on R & D to meet the world's urgent eye care needs. In addition, Alcon has established a close partnership with eye care professionals and humanitarian organizations to focus on medical missions and carry out anti blindness activities in communities in need of assistance around the world. There are many unsolved ophthalmic problems in the world, millions of people in the world can not get routine ophthalmic care, and a lot of substantive work needs to be completed. Based on decades of professional experience, Alcon will continue to focus on promoting the development of eye care industry. Alcon entered China as a legal entity in 1995. Today, Alcon China has more than 700 employees serving our eye care experts nationwide. Our business goal is to be the choice of patients in the field of surgical products, drugs and vision care. Elkon China has always adhered to its commitment to Chinese ophthalmologists and patients, and constantly strengthened mutual cooperation to create a brilliant tomorrow hand in hand. Erkang China, in close cooperation with the ophthalmology branch of the Chinese Medical Association, has held various scale and types of academic seminars, national annual ophthalmology conference and international ophthalmology conference, created a platform for academic exchange activities of domestic ophthalmologists, and made unremitting efforts to promote the development of ophthalmology in China. In addition, elkham China has also worked closely with China Disabled Persons' Federation, health express and other charities to support various poverty alleviation projects and contribute to China's anti blindness work.

本文链接: https://brand.waitui.com/ed7309435.html 联系电话:400-621-3132

千城特选小程序码

7×24h 快讯

千红制药:预计2024年归母净利润3.2亿元-3.8亿元,同比增长75.96%-108.95%

36氪获悉,千红制药发布2024年业绩预告。报告显示,预计2024年归母净利润3.2亿元-3.8亿元,同比增长75.96%-108.95%。2024年度销售收入虽因药品价格下降而下降,但主要产品销量均保持增长且毛利率较上年同期持续提升,由此归母净利润实现了同比较大幅度提升。

2小时前

飞荣达:子公司拟3.8亿元收购江苏中煜100%股权

36氪获悉,飞荣达公告,公司全资子公司江苏飞荣达拟收购江苏中煜橡塑科技有限公司(简称“江苏中煜”)100%股权,交易价格为3.8亿元。标的公司是一家以高端橡胶密封件及新能源汽车橡胶制品生产销售为一体的制造型企业,并拥有专业的橡胶材料研发的技术团队。本次收购将丰富公司在新能源领域的产品矩阵,增强公司电磁屏蔽及热管理解决方案的综合能力,有效实现资源整合及业务协同,有利于提升公司综合竞争力及市场份额。

2小时前

中航电测:拟变更证券简称为“中航成飞”

36氪获悉,中航电测公告,公司于2025年1月22日召开2025年第一次临时股东大会,审议通过了《关于变更公司名称、证券简称、经营范围及修订的议案》《关于变更公司证券代码的议案》。公司拟将证券简称由“中航电测”变更为“中航成飞”,英文简称由“ZEMIC”变更为“AVIC CAC”。本次变更后的证券简称及证券代码拟启用日期待定,以深圳证券交易所最终核准的日期为准。公司特别提示广大投资者充分知晓。

2小时前

支付宝:“碰一下钱被隔空盗刷”系摆拍,部分造谣者已被惩处

36氪获悉,据支付宝安全中心微博,近期,部分自媒体为吸引眼球和流量,发布摆拍虚假视频,捏造“使用支付宝碰一下钱被隔空盗刷”等不实内容。经公安机关依法办案,部分造谣者已受到应有的惩处。

2小时前

欧盟据悉提议成立专注于AI等战略技术的高级研究机构

据报道,欧盟将提议仿照美国政府建立一个高级研究项目机构,投资战略技术。欧盟还将呼吁为人工智能建设新的超级计算基础设施。据知情人士和文件消息,这些计划已被纳入欧盟将于1月底发布的新战略草案中,同时发布的还有关于削减监管、改善资金获取、降低能源成本和减轻与关键材料相关的依赖性的建议。(界面)

2小时前

本页详细列出关于Medtronic美敦力的品牌信息,含品牌所属公司介绍,Medtronic美敦力所处行业的品牌地位及优势。
咨询